ストックスクリーナーアプリを入手
558.01
5.16%
-30.39
アフターアワーズ：
558.01
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday - Finviz
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.4%Time to Sell? - MarketBeat
Madrigal Pharmaceuticals (MDGL) Downgraded Amid Valuation Concer - GuruFocus
Wolfe Research downgrades Madrigal Pharmaceuticals stock on valuation concerns By Investing.com - Investing.com UK
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - AOL.com
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data (NASDAQ:MDGL) - Seeking Alpha
Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade - Seeking Alpha
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
MASH Treatment Market Competition Analysis 2025: How Players Are Shaping Growth - EIN News
(MDGL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
4,485 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Calamos Advisors LLC - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Madrigal Pharmaceuticals expands workforce with new equity grants to staff - MSN
Madrigal Pharmaceuticals Earnings Notes - Trefis
Here are the most and least likely M&A targets in biotech, according to Truist - MSN
Madrigal uses equity incentives to lure talent as MASH drug scales up - MSN
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockLarge Cap Stability Picks & Consistently Superior Profits - earlytimes.in
Madrigal Uses Equity Incentives to Lure Talent as MASH Drug Scales Up - MyChesCo
Madrigal Heads to JPMorgan as MASH Drug Puts Company in the Spotlight - MyChesCo
Madrigal Pharmaceuticals (MDGL) Is Up 5.4% After REZDIFFRA Phase 3 Data And CFO HireHas The Bull Case Changed? - Sahm
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 605.86 USD By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 52-Week HighHere's What Happened - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 605.86 USD - Investing.com
Voya Investment Management LLC Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
(MDGL) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Bullish Rezdiffra Data, FDA Designations and Analyst Upgrades - Sahm
Trend Report: How strong is Madrigal Pharmaceuticals Inc stock revenue growthQuarterly Profit Review & AI Forecasted Entry and Exit Points - moha.gov.vn
Madrigal Pharmaceuticals Stock Soars as Analysts Raise Price Targets - StocksToTrade
Madrigal Pharmaceuticals Sees Bullish Price Target Increases Amid Market Excitement - timothysykes.com
What consensus target says about Madrigal Pharmaceuticals Inc. (YDO1) stockJuly 2025 Catalysts & Safe Capital Preservation Plans - ulpravda.ru
Madrigal Pharmaceuticals Sees Steady Surge with Revised Analyst Ratings - StocksToTrade
Madrigal Pharmaceuticals Sees Optimistic Price Target Upgrades Amid Expansion Expectations - StocksToTrade
Madrigal Pharmaceuticals’ Stock Surge: Analyzing Latest Price Target Upgrades - timothysykes.com
Madrigal Pharmaceuticals Sees Price Targets Raised Amid Rezdiffra Optimism - timothysykes.com
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1‑Year Share Price Surge - Yahoo Finance
Piper Sandler Raises Price Target for MDGL to $900, Maintains Ov - GuruFocus
Piper Sandler raises Madrigal Pharmaceuticals stock price target to $900 on MASH opportunity - Investing.com UK
Will Madrigal Pharmaceuticals Inc. stock split attract more investorsGDP Growth & Free Community Consensus Stock Picks - DonanımHaber
Piper Sandler Raises Price Target for MDGL to $900, Maintains Overweight Rating | MDGL Stock News - GuruFocus
Will Madrigal Pharmaceuticals Inc. stock outperform value stocksRisk Management & Growth Oriented Trade Recommendations - DonanımHaber
Madrigal Pharmaceuticals price target raised to $900 from $540 at Piper Sandler - TipRanks
Is Madrigal Pharmaceuticals Inc. stock a top momentum playMarket Performance Recap & Long-Term Safe Investment Plans - Улправда
Madrigal Pharmaceuticals Inc (HAM:YDO1) Stock Earnings Transcripts - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal Pharmaceuticals (HAM:YDO1) EV-to-OCF : -64.02 (As of Dec. 18, 2025) - GuruFocus
Madrigal Grants New Equity Awards as Hiring Builds Momentum Around MASH Drug - MSN
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Marex Group plc Buys New Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):